“以人为本”建立中医药实体瘤疗效评价标准

"People-centered" therapeutic efficacy assessment criteria for Chinese medicine on solid tumor

从"以人为本"的角度探讨中医药实体瘤疗效评价标准的建立方法。根据肿瘤治疗理念的变化和中医药治疗肿瘤的疗效特点,结合国内外有关肿瘤药物评审标准的变化情况,认为中医药治疗恶性肿瘤的疗效评价标准应以体现病情稳定的无病生存期、无进展生存期为首要评价指标,并引入国际通用的生存质量、实体瘤肿瘤负荷变化等指标,中医证候是否应该作为疗效评价依据值得商榷。

This paper discusses the therapeutic efficacy assessment criteria for Chinese medicine on solid tumor form ＂people-centered＂ point of view. Based on changes of treatment idea and therapeutic effect of Chinese medicine for tumor, and combined with domestic and overseas assessment criteria, this paper views that the therapeutic efficacy assessment criteria of Chinese medicine should reflect the stability of disease, and the evaluation indexes include disease-free survival and progression free survival. Some international indexes, such as quality of life and the tumor burden were introduced in this paper. Whether the TCM syndrome can be the evaluation index needs to be studied.